Biotech company Virogates receives new investment  

The Danish company has received DKK 2.5 million from investors to complete the development of its first diagnostic product, suPARnostic

Biotech company Virogates has received DKK 2.5 million (USD 425,000) from a group of investors including DTU Innovation and MissionPharma. A further DKK 2.5 million is expected from investors in February. The money will be used to complete the development of Virogates' first product, suPARnostic, a new low-cost HIV test which is expected to reach the market at the end of 2004.


SuPARnostic equipment can measure the molecule suPAR (the technical abbreviation for soluble urokinase Plasminogen Activator Receptor) in people with HIV. The content of this molecule gives important information about when treatment should be started. According to Virogates suPARnostic can be sold at much cheaper prices than corresponding products on the world market. Virogates hopes it will gain a leading position as supplier of cheap HIV tests in the third world. The news is reported by BiotechDenmark online.


Link > Virogates

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×